MediPrint Ophthalmics is a clinical-stage San Diego eye‑care pharmaceutical company developing a proprietary contact lens drug‑delivery platform. Its lead asset, LL‑BMT1, is a weekly medicated contact lens releasing bimatoprost to treat open‑angle glaucoma and ocular hypertension; a Phase 2a SIGHT‑1 study showed safety, tolerability, and a positive efficacy signal. The company is advancing LL‑BMT1 into a dose‑escalating Phase 2b clinical trial planned for 2022 and intends to hold an end‑of‑Phase‑2 meeting with the FDA. Raised Series A proceeds will fund the upcoming Phase 2b and other product advancement, notably a dry eye asset, into clinical trials. MediPrint highlights a market opportunity among over 40 million U.S. soft contact lens wearers and notes that approximately 5% of U.S. glaucoma patients wear contact lenses. The company presents its Phase 2a clinical results to the American Glaucoma Society, and says the financing plus professional reception further validate its platform. Leo Lens Pharma is developing a proprietary continuous ocular drug-delivery portfolio built around a drug-eluting, comfort-enhancing contact lens using its patented MediPrint™ process. The company has submitted an IND to the U.S. FDA for its lead asset, LL-BMT1, a key step toward beginning its first in-human clinical trial. Plans call for enrollment of the first patients in a Phase 2a study in the coming months. Leo Lens is also building a product pipeline for dry eye, allergy, and other anterior segment conditions. The company highlights a large unmet need versus eye-drop therapy, noting eye drops remain standard of care for over 90% of patients but have roughly a 50% compliance rate, and cites a $4B U.S. market opportunity. Recent seed funding will be used to support the Phase 2a clinical study and an end-of-Phase 2 meeting with the FDA.

Total raised

$6M

Funding rounds

2

Latest round

Series A

Latest activity

Mar 2022